FogPharma
Mathai Mammen, M.D., Ph.D., will join the company as chairman, president and chief executive officer. Dr. Mammen brings significant global R&D and corporate leadership experience to FogPharma, having most recently served as executive vice president, pharmaceuticals, R&D, at Johnson & Johnson. Prior to that, Dr. Mammen served in senior R&D roles at Merck, Inc., having begun his career as founder and head of R&D at Theravance, Inc. Dr. Mammen will serve as an advisor to FogPharma beginning immediately and will assume his position as chairman, president and chief executive officer in June 2023. FogPharma founder Gregory Verdine, Ph.D., will transition from his current role as chairman and chief executive officer to vice chairman on the company’s board of directors.
This person is not in any teams
FogPharma
1 followers
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention.